Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial
B. Hartley (Twickenham, United Kingdom), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), P. Jones (Brentford, United Kingdom), C. Crim (Research Triangle Park, NC, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Singh (Manchester, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), N. Barnes (Brentford and London, United Kingdom)
Source: International Congress 2019 – Exacerbations of airway diseases
Session: Exacerbations of airway diseases
Session type: Poster Discussion
Number: 5230
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Hartley (Twickenham, United Kingdom), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), P. Jones (Brentford, United Kingdom), C. Crim (Research Triangle Park, NC, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Singh (Manchester, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), N. Barnes (Brentford and London, United Kingdom). Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial. 5230
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: